bu-abdullaziz
عضو مميز
- التسجيل
- 11 ديسمبر 2003
- المشاركات
- 1,777
Lebed.biz Stock Profiles:
January 3rd, 2005:
We are profiling ChromaVision Medical Systems Inc. (CVSN) at $2.12 as a short-term strong buy.
CVSN develops, manufactures and markets an automated digital microscope system with the ability to detect, count and classify cells based on color, size and shape to assist pathologists in making medical decisions that can affect patient treatment.
CVSN grew revenues from $4.8 million in 2001 to $9.2 million in 2002 and $11.9 million in 2003.
CVSN recently announced that its new Irvine, CA laboratory facility has received a license from the State of California Department of Health Services and is now able to begin providing a wide range of esoteric cancer tests.
CVSN also recently completed the acquisition of the business and substantially all of the assets of Laureate Pharma L.P. of Princeton, NJ for approximately $29.5 million. Laureate Pharma had 2003 revenues of approximately $7.4 million. In the first nine months of 2004, Laureate Pharma's revenues were $8.1 million.
CVSN had more big recent news about the launch of its new Internet-based remote Access program, enabling even more laboratories to provide the quantitative diagnostic results necessary to prescribe today's leading, patient-appropriate cancer treatments.
After rising from below $1 in November CVSN appears to have built a lot of support at $2 and looks ready to rise even higher.
!
January 3rd, 2005:
We are profiling ChromaVision Medical Systems Inc. (CVSN) at $2.12 as a short-term strong buy.
CVSN develops, manufactures and markets an automated digital microscope system with the ability to detect, count and classify cells based on color, size and shape to assist pathologists in making medical decisions that can affect patient treatment.
CVSN grew revenues from $4.8 million in 2001 to $9.2 million in 2002 and $11.9 million in 2003.
CVSN recently announced that its new Irvine, CA laboratory facility has received a license from the State of California Department of Health Services and is now able to begin providing a wide range of esoteric cancer tests.
CVSN also recently completed the acquisition of the business and substantially all of the assets of Laureate Pharma L.P. of Princeton, NJ for approximately $29.5 million. Laureate Pharma had 2003 revenues of approximately $7.4 million. In the first nine months of 2004, Laureate Pharma's revenues were $8.1 million.
CVSN had more big recent news about the launch of its new Internet-based remote Access program, enabling even more laboratories to provide the quantitative diagnostic results necessary to prescribe today's leading, patient-appropriate cancer treatments.
After rising from below $1 in November CVSN appears to have built a lot of support at $2 and looks ready to rise even higher.
!